Bruton's tyrosine kinase (BTK) is highly expressed and activated in more than 90% of acute myeloid leukemia (AML) cases. 1, 2 An important contribution of BTK has been reported in the context of FLT3-ITD-positive AML 2 and is involved in signaling pathways of Toll-like receptors, 3 nuclear factor κB (NFκB) 2 and chemokine receptor CXCR4. 4 Expression and activation of BTK are associated with poor prognosis of AML patients. 2, 5 The mixed-lineage leukemia (MLL) gene is frequently disrupted by chromosomal rearrangements and is associated with distinct clinical features and poor prognosis. Human cord blood hematopoietic CD34+ progenitor cells transduced with MLL-AF9 (MA9) maintain a myelomonocytic AML-like phenotype in cytokine-supplemented medium. 6 The cells induce leukemia in non-obese diabetic/severe combined immunodeficiency mice representing a human model of MA9-positive leukemia. 6 The specific contribution of BTK in MLL-rearranged AML (MLL-AML) is not known. Because an essential role of NFκB signaling by MLL oncoproteins in the maintenance of leukemic stem cells was reported, 7 we investigated the contribution of BTK and p65 in MLL-rearranged leukemia.
Whole cell lysates from AML cell lines ( Figure 1a , left panel), cord blood CD34+ cells (CB1 and 2), MA9 clones 3 and 6 (MA9.3 and 9.6; Figure 1a , middle panel) and leukemic blasts from MLL-AML patients and CB2 ( Figure 1a , right panel; Supplementary  Table 1) were probed for the expression and phosphorylation of p65 (pS536) and BTK (pY223). Interestingly, AML cell lines with MLL rearrangements (MOLM-13 and THP-1), both MA9 clones and AML patients (AML 2 and 3) indicated constitutive phosphorylation of both p65 and BTK, albeit to different degrees. Importantly, short-term treatment of MA9.3 and MOLM-13 cells with BTKspecific inhibitor, ibrutinib, inhibited the phosphorylation of BTK and p65 in a dose-dependent manner (Figure 1b note, ibrutinib treatment had no effect on cell cycle distribution (Supplementary Figure 3D) and failed to induce cell death (Supplementary Figure 3E) in the non-MLL-rearranged AML cell line, OCI AML3. Daunorubicin (a standard chemotherapy drug in AML) in combination with ibrutinib further sensitized the cells and induced a strong effect on cell viability (Figure 1d, right panel) . The nature of drug interaction (ibrutinib: daunorubicin) was analyzed by calculating the coefficient of drug interaction (CDI) value. 10 CDI values o 1.0 indicated that daunorubicin synergistically increased the cytotoxic efficacy of ibrutinib (Supplementary Table 2 ). Control cells treated under identical conditions were nonresponsive to ibrutinib treatment. Collectively, the data indicate a pivotal role for activated BTK in MLL-rearranged leukemic cells and inhibition of BTK activity affected cell viability in MA9.3 cells.
RAC GTPases (RAC1, RAC2 and RAC3) act as a molecular switch in multiple cellular processes that affect cancer progression, cell cycle progression, cell survival and including cytoskeletal dynamics. 11 Previous studies have established a positive relationship between small Rho GTPases RAC1, 2 and MA9 rearrangements. 6, 12 BTK has an important role in the migration of mouse bone marrow-derived mast cells in response to chemo-attractants via RAC activation. 13 It is therefore tempting to speculate on a role for BTK in the activation of RAC1. RAC1-GTPase activation assays were performed in MA9.3 cells treated with DMSO and ibrutinib (Figure 2a ). In line with observations by others, 6, 12 we identified RAC1-GTP in DMSOtreated cells. Interestingly, ibrutinib treatment significantly reduced RAC1 activation. Similar data were observed in MOLM-13 cells but not in non-MLL-rearranged cell line OCI AML3 (Supplementary Figures 4A and B) . The findings thus underscore the contribution of activated BTK in the activation of RAC1-GTPase. RAC inhibitor treatment, NSC23766, affected MA9.3 cell viability. 6, 12 As BTK lies upstream of RAC1 and is playing a functional role in cell survival (Figures 1b and d) , we hypothesized that ibrutinib treatment might increase the efficacy of RAC inhibition. MA9.3 cells were treated with various doses of NSC23766 (5, 10, 15 and 20 μM) alone or in combination with clinically relevant doses of ibrutinib (0.5 μM; Figure 2b ). The drugs were more potent in combination and CDI values indicated synergism between NSC23766 and ibrutinib (CDI o1.0; Supplementary Table 3) . Again, control cells (CB-CD34+) were inert to the inhibitor treatment. Of note, short-term NSC23766 treatment did not affect p65 phosphorylation, suggesting RAC1 inhibition-induced cell death is independent of changes in p65 phosphorylation (Supplementary Figure 5) . These observations collectively highlight the dependency of the MA9.3 cells on BTK activation and its downstream signaling for cell survival. Bone marrow stroma and stromal cell-derived soluble factors have been implicated in the cytoprotection of AML cells.
2,14 So we further investigated in this direction. Short-term treatment of serumstarved MA9.3 with HS5 conditioned medium resulted in the phosphorylation of BTK and p65 (Supplementary Figures 6A-C) . Gαq protein directly stimulated the activity of purified BTK. 15 Furthermore, an important role for CXCR4 and Notch signaling in the hematopoietic stem cell microenvironment has also been described. 16, 17 Therefore, we used pharmacological inhibitors to disrupt signaling at the receptor level (CXCR4 antagonist e.m. *P o0.05, **P o0.01, ***P o0.001 and ****P o0.0001. AMD3100, gamma-secretase inhibitor XII (GSI XII) to block Notch activation) and at the level of heterotrimeric G protein function (FR900359 and BIM46187). 18, 19 MA9.3 cells were pre-treated with various inhibitors and analyzed for activation of BTK and p65 ( Supplementary Figures 6D and E) . Interestingly, pan G protein inhibitor BIM46187 induced phosphorylation of BTK and p65, whereas no such effect was noted using Gαq/11-specific inhibitor FR900359, AMD3100 or GSI XII. The inhibitors also failed to block phosphorylation on BTK and p65, indicating the Gαq/11 family of G proteins, CXCR4 and Notch signaling is not involved in activation of BTK and p65. We next used human bone marrow stromal cells (HS5) and primary stromal cells and investigated whether BTK-RAC1 inhibition would block the protective effects of stromal cells. Compared to MA9.3 cells without stromal cell support, MA9.3 cells cocultured with HS5 (Supplementary Figure 7A) or primary bone marrow stromal cells (Supplementary Figure 7B) were resistant to the cytotoxic action of ibrutinib and showed reduced cytotoxicity to NSC23766. However, in comparison to single drug treatment, a combination of ibrutinib and NSC23766 demonstrated considerable induction of cell death (Supplementary Figures 7A and B) .
These findings expand our current understanding of the multiple mechanisms by which MLL rearrangements regulate cellular viability. Specifically, we demonstrate the contribution of aberrantly active BTK and p65 in cells with MLL rearrangements. The effect of ibrutinib on MA9.3 cells indicates specific vulnerability of MLLrearranged leukemia to BTK inhibition. Our results may provide the basis for future clinical trials with ibrutinib used as a single agent or in combination with daunorubicin or RAC1 inhibition. This strategy might benefit MLL-rearranged AML where there is a high risk of relapse and resistance to conventional chemotherapy.
